Comments for GENZ - Stockpickr! Your Source for Stock Ideas

Comments for GENZ

Added By	Comments	Type	Date Added
barrons3	Could the defensive stocks be hated more? Could someone sell Genzyme (GENZ) lower?	Love	August 06, 2009
barrons3	Genzyme (GENZ) pulled back on Tuesday, reminds host Melissa Lee. Is that a buying opportunity? I’d wait, counsels Pete Najarian. It’s bounced off this level many times.	Love	June 17, 2009
Stockpickr Staff	"The Nasdaq united will never be defeated. For those of you who were protestors for just about every cause at college, you know that familiar ditty, except it was "the people" back then. But I keep thinking about it because of how united the Nazz is on days like today, with every oar pulling in the right direction, from restaurant chains to tech (particularly cell phone tech, which I have pushed endlessly) to biotech (thanks Genzyme (GENZ) to infrastructure plays like Bucyrus (BUCY) and Joy Global (JOYG)." (<a href="http://jimcramer.rmblogs.thestreet.com/entry.aspx?q=1c5c6dae-5424-476f-b8eb-9c2200b3ea71" target="_blank">"You Can't Stop This Nasdaq Juggernaut," 6-9-09</a>)	Love	June 10, 2009
sarah z	“Is health care finished as a concept? I think that you could argue that it is finished as a hiding place. The health care business has been rocked by problems before, and it has managed to bounce back time and again, but this one's really painful because there's nothing but bogeymen out there telling us what is going to happen. We are in a "shoot first, ask questions later" mode. One thing I would point out is that the drug industry has been a remarkable stalwart in Congress, and the president's going to have a tougher time rolling them that he would other industries. The real issue for me is valuation. Let's say the president doesn't want Genzyme (GENZ) to get reimbursed the way it has been for orphan drugs. It's been the Democrats, not the Republicans, who have fought for these companies. The Democrats have always held up the group as inventors, not salespeople, so my take is that after the smoke clears, you will come back to that group. But is now the time to buy them? I think their outperformance has been too great in the last six months to call a bottom, and the big pharma companies are reeling, too. Would I short them here? You should have shorted them two days ago. Going long, though? I'd wait, which is why we trimmed the group yesterday for Action Alerts PLUS. My instincts, given congressional love for biotech, though, is that when they settle, you will be surprised the resistance that Obama gets on the issue, particularly the orphan drug issue.”	Love	February 27, 2009
barrons3	So now they are coming for everything in the sector, as reimbursements could be cut for everything. That means some pain in Genzyme (GENZ), which has high-priced drugs that may not be protected.	Love	February 26, 2009
barrons3	In the larger space I like Celgene [CELG], Genzyme [GENZ] and Teva [TEVA] for their pipelines. - Pete Najarian	Love	February 18, 2009
Alan Ellison	Looks like a winner.	Love	January 31, 2009
barrons3	In addition, Huckman also thinks there could be news out of Genzyme [GENZ], Celgene [CELG] and Amgen [AMGN] three other presenters. They could re-affirm their guidance, or provide color on Q4 revenue which would, in turn, move their stocks, he says.	Love	January 14, 2009
Trading Nymph	9	Love	December 30, 2008
barrons3	You want hypergrowth? You can buy Celgene (CELG) or Gilead (GILD) or Amgen (AMGN) or Genzyme (GENZ).	Love	December 18, 2008
sarah z	From a recent Mad Money show:"I can't believe how much this one got slammed today. This is one you buy into on the way down. I'm a buyer of Genzyme right here."	Love	December 02, 2008
barrons3	Pesek also likes Cambridge, Mass.-based Genzyme (GENZ), a biotech outfit focused on diseases stemming from enzyme disorders. "Its small nichey markets provide an opportunity to raise prices," Pesek says, noting that many of its pipeline products -- such as Myozyme, for treating often-fatal Pompe disease, which can affect muscles and the heart, and Mozibil, used to increase stem-cell counts in transplants -- benefit from orphan-drug status. Campath, for multiple sclerosis, differs because it has a potentially enormous market. The National MS Society estimates that about 200 Americans are diagnosed with this auto-immune disease every week. Overall, there are about 400,000 people in the U.S. and more than 2.5 million people worldwide suffering from MS. "Management believes they can achieve a compound annual growth rate in earnings per share of 20% from 2007-2010, and if pipeline products are successful that will be even better," Pesek says. He added to his Genzyme stake in the summer of 2007 when the stock was trading in the low to mid-60s. More recently, it's been trading at 70.20. The consensus estimate for Genzyme's EPS is $3.97 in '08, $4.73 in '09 and $5.55 in '10. Its price-to-earnings multiple works out to about 15 times '09 estimates.	Love	November 01, 2008
barrons3	The derivatives are more powerful than the stocks they encompass -- Nasdaq or S&P futures -- but they are not more powerful than the companies themselves. Genzyme (GENZ), Gilead (GILD), Hologic (HOLX), Starbucks (SBUX), they will all get killed. Is that right? I don't think so.	Love	September 18, 2008
stockerblog	products and therapies relating to renal, therapeutics, transplants, biosurgery, and genetics	Love	May 10, 2008
barrons2	check out Genzyme (GENZ) and Isis (ISIS) for their diabetes and cholesterol franchises.	Love	April 02, 2008
JAEdwards	Biotech medical player	Love	March 31, 2008
moab_troy	Great future	Love	March 02, 2008
Adrian Smith	Lost many dollars	Hate	February 26, 2008
gvphubli	Earnings Stability Rating: 3. Biotech large cap’s industry group is one of the best-performing over the past six months. Five-year earnings growth rate: 27%.	Love	January 28, 2008
Jr Birdman	made money	Love	January 14, 2008
High Dividends	Icahn	Love	December 23, 2007
badkins729650	growth	Love	December 17, 2007
tejakota	Revenues in current quarter grew by 900%.Stock has room to grow atleast 40% from todays level of 73 to justify its growth.	Love	November 02, 2007
stephaniezoidis	healthcare growth takeover possibilities	Love	October 28, 2007
sefredri	Likely to be one of the successful biomedical with profitable drugs in late stage development	Love	September 27, 2007
great stock picker	out classed by competition	Hate	September 10, 2007
guynhalf	orphan drug specialist	Love	September 09, 2007
CagneyC	#43	Love	August 26, 2007
Lucklesshero	Undervalued.	Love	August 22, 2007
speedybure	I cant say enough great things about the company. Good drugs already approved and a fantastic pipline(5 drugs in stage 3 trials, that will be goto the fda for approval. The have a forward p/e between 15-16 and my dcf model estimated it is worth 74-80/share their ceo said in the conference call they expect to grow earnings 20% for the next 5 years. PLus they cater to niche diesease, or ones that effect small populations of people. This mean they get orphan drug status so if approved their is a very long patent. Plus there is very little competition.	Love	August 18, 2007